Type of Assessment:
Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement
Journal of Thoracic Oncology 2026 June 20 [Link] Shinichiro Suzuki, Kaushal Parikh, Ezequiel Tolosa, Kuan-Li Wu, Rohini Mopuri, Jennifer Ayers-Ringler, Lin Yang, Kim P Lauer, Katherine E R Smith, Yan W Asmann, Anja Roden, Farhad Kosari, Aaron S Mansfield Abstract Introduction: Diffuse pleural mesothelioma (DPM) is a lethal malignancy with no approved therapies directly targeting…
Read MoreCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MoreDevelopment and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
The Lancet, Oncology 2026 July [Link] Kevin B W Groot Lipman, Rianne Wittenberg, Mateus de Oliveira Taveira, Illaa Smesseim, Alexander M Th Schmitz , Thierry N Boellaard 2, Kalina Chupetlovska, Mohamed A Abdelatty, Liliana Petrychenko, Neeraj Jain, Francesco M Arico, Valerio Pugliese, Robin Cornelissen, Ties A Mulders, Fenneke Zwierenga, Birgitta I Hiddinga, Mena Shenouda, Samuel…
Read MoreExtracellular stressors change BBSome expression of benign mesothelial and primary pleural mesothelioma cells and affect cell adhesion and migration
Physiological Reports 2026 June [Link] Rajesh M Jagirdar, Erasmia Rouka, Eleanna Pitaraki, Sotirios I Sinis, Charalambos Varsamas, Eleftherios D Papazoglou, Lydia Giannakou, Panagiotis I Tzamalas, Ourania S Kotsiou, Anastasios Giannou, Chrissi Hatzoglou, Najib M Rahman, Konstantinos I Gourgoulianis, Sotirios G Zarogiannis Abstract Pleural mesothelial cells have a primary cilium (PC), a solitary sensory organelle facing…
Read MorePressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- ex vivo evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC)
Journal of Thoracic Disease 2026 May 31 [Link] Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, Arjang Ruhparwar, Hayan Merhej, Patrick Zardo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel…
Read MoreRejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma
Research 2026 June 11 [Link] Yan-Ruide Li, Yichen Zhu, Zhe Li, Xinyuan Shen, Shuo Li, Yuning Chen, Zibai Lyu, Jie Huang, Nathan Y Ma, Catherine Zhang, Annabel S Zhao, Yanxin Tian, Xianghong Jasmine Zhou, Lili Yang Abstract Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy arising from the pleural lining, characterized by…
Read MoreTrop-2 expression is associated with poor survival in pleural mesothelioma
Frontiers in Oncology 2026 May 29 [Link] Alejandro Aviles-Salas, Norma Hernández-Pedro, Enrique Caballé-Perez, José Lucio-Lozada, César Castillo-Ruiz, José Gregorio Chanona-Vilchis, Alejandro Aranda-Gutierrez, Mario Orozco-Morales, Pedro Barrios-Bernal, Rafael Parra-Medina, Luis Cabrera-Miranda, Andrés F Cardona, Oscar Arrieta Abstract Introduction: Pleural mesothelioma (PM) lacks reliable biomarkers to guide therapy. Trophoblast cell-surface antigen 2 (Trop-2) is targetable in epithelial…
Read MoreThe diagnostic performance and clinical value of [18F]FDG PET/CT in pleural mesothelioma – A systematic review and meta-analysis
Seminars in Nuclear Medicine 2026 June 10 [Link] Anne H Thostrup, Natasja U Stubbe, Mathias P Schreiner, Morten Bentestuen, Anne V Olesen, Helle D Zacho Abstract Purpose: This systematic review and meta-analysis aims to evaluate the diagnostic accuracy of FDG PET/CT for diagnosing pleural mesothelioma in treatment-naïve patients using histopathology as reference standard. Secondary aims…
Read MoreTumor treating fields in malignant pleural mesothelioma: from cytoskeletal collapse to immunophenotypic conversion
Frontiers in Oncology 2026 May 26 [Link] Xiaofeng Ma, Zhuo Zuo, Yulong Sun, Hong An Abstract The therapeutic efficacy in malignant pleural mesothelioma (MPM) is severely hindered by its dense stromal barrier and immunosuppressive microenvironment. Although Tumor Treating Fields (TTFields) have demonstrated significant survival benefits in clinical trials, their underlying mechanisms extend well beyond simple…
Read MoreKi67 proliferation index augments two-tier tumour grade in prediction of survival and progression-free survival in epithelioid pleural mesothelioma
ERJ Open Research 2026 June 8 [Link] Geraldine A Lynch, Yu Zhi Zhang, Nidhi Bhatt, Pia Charters, Avinash Aujayeb, Saru Walker, Jenny Symonds, Amelia O Clive, Rahul Bhatnagar, Anna Morley, Paul White, Andrew G Nicholson, Nick A Maskell, Anna Bibby Abstract Background: Pleural mesothelioma (PM) is a fatal asbestos-related cancer with a poor and often…
Read More
Skip to content